Skip to main content
. 2014 Nov 20;112(2):313–318. doi: 10.1038/bjc.2014.561

Figure 2.

Figure 2

(A) Progression-free survival with anti-EGFR therapy based on TL independent of KRas status. Data on TL and clinical outcome in 75 patients treated with anti-EGFR therapy, independent of KRas status. The patients with longer TL had a superior PFS than patients with shorter TL (HR 0.549, P=0.026). (B) Progression-free survival with anti-EGFR therapy in KRas WT patients based on TL. The analysis was narrowed down to the patients who were WT for KRas. Again, patients with longer TL had a superior PFS than patients with shorter TL, but with a better HR of 0.31 (P=0.048).